Key Highlights

  • Lunai Bioworks (NASDAQ:LNAI) fell 14.12% to USD 0.2530 in early trading on Monday, October 26, 2026, with Nasdaq trading expected to be suspended on Friday, October 30, 2026 and no over-the-counter quotation planned.
  • 22nd Century Group (NASDAQ:XXII) fell about 48.5% to USD 0.1019 from a prior close near USD 0.1977, with cash of USD 3.9 million at quarter end and 3,416,441 shares outstanding.
  • Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) fell 16.10% to USD 0.2601 with going-concern doubt and reverse-split authority, and Rubico (NASDAQ:RUBI) fell 9.41% to USD 0.1540 after a USD 8.5 million convertible note deal.
  • Only Lunai has a dated exit; the other three trade at pennies with funding needs that point to dilution or consolidation, and none has issued a release explaining Monday.

Lunai Bioworks (NASDAQ:LNAI): a dated exit from Nasdaq

Lunai Bioworks (NASDAQ:LNAI), an artificial intelligence drug discovery and biodefence company, traded at USD 0.2530 in early trading on Monday, October 26, 2026, down 14.12% after a Friday close of about USD 0.29. The driver is the company's release of Thursday, October 22, 2026, which disclosed that Nasdaq staff had determined to delist the shares because it no longer meets the minimum stockholders' equity requirement. The company will not request a hearing. Market value is near USD 1.3 million, based on the Friday close. The company also fails the alternative market value and net income tests and is under a mandatory panel monitor, which is why the staff acted directly.

The board approved voluntary delisting and deregistration. Trading is expected to be suspended at the open on Friday, October 30, 2026, Form 25 is planned on or about Monday, November 2, 2026 and delisting is expected around Thursday, November 12, 2026. Stockholders' deficit was USD 9,024,946 at June 30, 2026, against a required USD 2,500,000. The company does not intend to arrange over-the-counter quotation, which could leave holders with no public market and less information once SEC reporting ends. A published summary of the annual report cites a net loss of USD 3.56 million and a going-concern warning, and selling ahead of the suspension could add pressure. Investors should watch the final session on Thursday, October 29, 2026.

22nd Century Group (NASDAQ:XXII): cash of USD 3.9 million after a halving

22nd Century Group (NASDAQ:XXII), a tobacco company focused on reduced nicotine cigarettes, fell about 48.5% to USD 0.1019 in early trading on Monday, October 26, 2026. The company has not issued a release explaining the move. Preliminary unaudited third-quarter results of Thursday, October 22, 2026 showed revenue of about USD 4.8 million, up from USD 2.9 million in the second quarter, and a net loss of USD 2.6 million.

Growth arrived with a shrinking cash balance, which governs small-company prices. Cash and equivalents fell by USD 2.2 million to USD 3.9 million, so the balance covers roughly two quarters of losses before new funding, an inference from the reported figures. With 3,416,441 shares outstanding, a single issuance could change ownership materially. The company has not reported a listing notice, although a price below USD 1.00 raises compliance questions. The proposed federal nicotine limit has not been finalised, and the new Pinnacle Pure varieties are expected to ship in December 2026. Full results are due on or before Friday, November 13, 2026.

Lakewood-Amedex (NASDAQ:LABT): going-concern doubt and consolidation authority

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT), a clinical-stage developer of Bisphosphocin antimicrobial compounds, traded at USD 0.2601 in early trading on Monday, October 26, 2026, down 16.10% from a Friday close of about USD 0.31. The company has not issued a release explaining the move. It presented Nu-3 antimicrobial data at IDWeek 2026 on Wednesday, October 21, 2026. About 2.4 million shares are outstanding, which implies a market value near USD 0.6 million.

The balance sheet adds pressure. A raise of USD 7.5 million in 12% preferred stock was registered in August 2026, and the related quarterly report flagged going-concern doubt. Shareholders approved reverse-split authority on Monday, September 28, 2026, and a proxy sought authorisation for 100 million shares. Operating cash outflow for 2025 was about USD 1.9 million, and a current ratio of 0.13 shows liabilities far above liquid assets. A minimum bid price notice has not been disclosed. Preclinical results do not guarantee human efficacy, and the company has no approved product.

Rubico (NASDAQ:RUBI): convertible notes priced against a USD 0.15 share

Rubico (NASDAQ:RUBI), which reports a net asset value as its main measure, fell 9.41% to USD 0.1540 in early trading on Monday, October 26, 2026. The company has not issued a release linking the move to a new event. On Friday, October 16, 2026 it announced a registered direct offering of senior convertible notes and warrants, with Maxim Group as sole placement agent. The first tranche carries USD 9,444,444 of principal for USD 8.5 million of gross proceeds, and a second tranche for up to USD 5.0 million is possible.

Notes convert at the lower of USD 0.3646 and 85% of the lowest daily volume weighted average price of the prior 10 trading days, with a USD 0.10 floor. With the shares near USD 0.15, the alternate formula would likely govern, an inference from the published terms. Warrants cover 25,903,577 shares. The USD 0.10 floor limits the price but not the number of shares issued, and a net asset value of USD 258.0 million, announced on Tuesday, October 20, 2026, is a company estimate and not a price target. A price well below USD 1.00 can trigger a Nasdaq minimum bid deficiency notice, which in turn can lead to another share consolidation.

Where Things Stand

The answer is that only Lunai Bioworks (NASDAQ:LNAI) has a dated exit, while the other names show the conditions that precede one. Lunai faces suspension on Friday, October 30, 2026 with a USD 9,024,946 deficit, 22nd Century Group (NASDAQ:XXII) has USD 3.9 million of cash after a fall of about 48.5%, Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) holds reverse-split authority with going-concern doubt, and Rubico (NASDAQ:RUBI) carries notes that convert at a discount. The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, Form 25 on or about Monday, November 2, 2026, 22nd Century results by Friday, November 13, 2026 and Rubico conversion filings. Delisted shares can become difficult to sell, and this is not investment advice.